SINGLE-ARM, PHASE 1B, OPEN-LABEL STUDY ASSESSING THE SAFETY, TOLERABILITY, AND PHARMACODYNAMICS OF REPEAT-DOSE SUBCUTANEOUS ANX009 PLUS STANDARD OF CARE IN ADULT PATIENTS WITH LUPUS NEPHRITIS (ISN-WCN 2023) - Mar 28, 2023 - Abstract #WCN23-0685; "Allowed stable background standard of care for LN and SLE include mycophenolate mofetil, azathioprine, antimalarials, glucocorticoids, cyclosporin, voclosporin, tacrolimus, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers. Results Results for this clinical trial are anticipated in mid-2023. Conclusions n/a"
Clinical • P1 data • PK/PD data • Chronic Kidney Disease • Glomerulonephritis • Immunology • Infectious Disease • Inflammation • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Renal Disease • Systemic Lupus Erythematosus
|
|
H.C. Chen; J.J. Lichauco; H.M. Gomez; M. Tee; C. Arroyo; J.L. Lan; Y.F. Fang; Q. Chang; J. Osterloh; A. Miles; E. Chang; A. Mongan; H.A. Kroon
|